Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,382 across all filing types
Latest filing 2014-02-05 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated February 5, 2014, announcing clinical results for Dysport® Next Generation (DNG) and Ipsen's intent to file for regulatory approval in Europe and ROW. It details Phase III and Phase II study outcomes, compares them to the existing Dysport®, and discusses safety profiles. This type of announcement, focusing on key clinical trial results and the subsequent intention to file, is characteristic of a press release detailing scientific/product development progress. It is not a comprehensive Annual Report (10-K), a formal Audit Report (AR), a full Earnings Release (ER) focusing on financial metrics, or a Call Transcript (CT). Since it is a specific announcement about product development and regulatory intent, it fits best as a general announcement that doesn't fit the highly specific categories like DIV, NAV, or DIRS. Given the options, it is a significant corporate announcement. While it contains scientific data, it is primarily an announcement of results and intent to file, making it a strong candidate for a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release, RNS serves as the best fit for significant, non-financial, non-governance specific corporate news that isn't a formal report itself.
2014-02-05 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated February 5, 2014, from Ipsen, announcing clinical trial results for Dysport® Next Generation (DNG) and the intention to file for marketing authorization (AMM). It details Phase III and Phase II study outcomes, includes quotes from the Principal Investigator and the CSO, and provides extensive background information on the product and the company. This format—a detailed announcement of significant operational/clinical progress intended for broad dissemination to investors and the public—is characteristic of an Earnings Release (ER) or a general press release announcing material news. Since it focuses on clinical trial results and future regulatory filings rather than just summarizing quarterly financial performance (which would be ER), and it is not a formal regulatory filing like a 10-K or a specific report like an AR or IR, it best fits the category of a general announcement of material information. Given the options, 'Earnings Release' (ER) is often used broadly for major operational updates that precede or accompany financial reporting, but 'Regulatory Filings' (RNS) serves as the best fallback for significant, non-standard announcements. However, because this is a detailed announcement of clinical trial results and strategic intent, it strongly resembles the content often found in an Investor Presentation (IP) or a detailed press release that might accompany an earnings report. Since it is not a presentation deck (IP) and not a short regulatory notice (RNS), and it contains more detail than a typical Earnings Release (ER) which focuses on financial metrics, I must re-evaluate. The content is a scientific/clinical update leading to a regulatory action. In many databases, detailed press releases about clinical trial outcomes are classified as Investor Presentations (IP) if they contain slides/data summaries, or sometimes as Regulatory Filings (RNS) if they are mandatory disclosures. Given the structure (headlines, bullet points of results, quotes, detailed study descriptions), it functions as a detailed informational release. Since it is not a formal financial report (10-K, IR, ER), and it's not a presentation deck (IP), the most appropriate category for a detailed, non-standard corporate announcement that isn't a specific report type is the general regulatory/news category, RNS. However, if we consider the intent to inform investors about major business developments (clinical success leading to filing), it often overlaps with ER content, but ER is defined as 'initial announcement of quarterly/periodical financial results (key highlights only)'. This document is not focused on financial highlights. Therefore, RNS (Regulatory Filings / General Announcement) is the most suitable fallback for this detailed clinical/strategic press release.
2014-02-05 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document is titled "Ipsen : chiffre d'affaires du 4 ème trimestre et de l'année 2013" (Ipsen: Revenue for the 4th Quarter and the Year 2013) and contains detailed financial tables showing revenue figures for Q4 2013 and the full year 2013, compared to 2012. It explicitly states that Ipsen published its revenue for the fourth quarter and the year 2013 on January 28, 2014. This content is a comprehensive report of financial results for a specific period (the full year and a quarter), which aligns perfectly with the definition of an Interim/Quarterly Report (IR), even though it covers the full year as well. It is more detailed than a simple Earnings Release (ER) which usually contains only highlights. Since it covers the full year and a quarter, and is a comprehensive financial statement for a period shorter than a year (the Q4 part) or the annual summary, IR is the most appropriate fit among the options, as 10-K is reserved for the official annual report filed with the SEC, and this appears to be a press release/financial update. Q4 2013
2014-01-28 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 95% confidence The document is titled "Ipsen: sales in the fourth quarter and full year 2013" and contains detailed tables and commentary on consolidated sales figures for the full year 2013 and the fourth quarter of 2013. It includes financial metrics, regional breakdowns, therapeutic area performance, and commentary from the CEO regarding the results. This content structure is characteristic of an Earnings Release (ER) or a comprehensive Interim/Quarterly Report (IR). Since the document covers the *full year* results (2013) and provides detailed financial breakdowns, it leans towards a comprehensive report, but the context of reporting quarterly results alongside annual results often places it in the category of an Earnings Release (ER) which announces the period's performance highlights, or an Interim Report (IR) if it were a half-year report. Given the focus on reporting the results for the period (Q4 and Full Year 2013) immediately following the period end, and the presence of management commentary on performance, 'ER' (Earnings Release) is the most appropriate classification for the initial announcement of these figures, even though it is quite detailed. It is not a 10-K (Annual Report) as it is focused on sales figures for a specific period and is dated January 28, 2014, which is too early for the full 10-K filing for the year ended December 31, 2013. It is not an 'IR' as that is typically for half-year reports, and this covers the full year. Therefore, ER is the best fit for a detailed sales announcement. FY 2013
2014-01-28 English
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 99% confidence The document is a press release dated January 22, 2014, announcing a new governance structure in the United States, specifically the appointment of Cynthia Schwalm to head the US Operations and the oversight role of CEO Marc de Garidel for the upcoming launch of Somatuline® in oncology. This announcement details changes in senior management roles and responsibilities within the company's leadership structure. This aligns directly with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2014-01-22 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release dated January 22, 2014, announcing significant changes in the US governance structure of Ipsen, specifically appointing Cynthia Schwalm to lead the US commercial operations and prepare for the launch of Somatuline® in oncology. It details management appointments and restructuring. This type of announcement, focusing on changes in senior management and board structure, directly aligns with the definition of Board/Management Information (MANG). It is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2014-01-22 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.